Interim report Q1/2024: MDR certification opens up great commercial opportunities
First quarter · Net sales reached SEK 9.4 (13.0) million. · The operating result totaled SEK -18.4 (-14.4) million. · Earnings per share, basic and diluted, were SEK -0.11 (-0.09). · Cash flow from operating activities totaled SEK -7.3 (-12.2) million. CEO Comment “Sales for the first quarter were lower than the same period last year, which in its entirety is due to the low partner sales. In the Swedish market, sales were up by 21% compared to the same quarter last year, and our market share continues to increase. During the quarter, ColdZyme was MDR certified as